Introduction
============

Maxillary sinus is the largest of the paranasal sinuses ([@ref-22]). It is bordered posteriorly by the pterygopalatine fossa and infratemporal fossa, inferiorly by the alveolar process and superiorly by the orbital floor ([@ref-22]). Unilateral maxillary occupying lesions encompass a broad array of pathologies, predominantly sinusitis, followed by sinus cyst, and then benign neoplasms (mostly sinonsal papillomas) ([@ref-6]). Because the maxillary sinus is the most frequent site of sinus pathologies, mere ostium opening by endoscopic approach may not adequately address all the problems ([@ref-13]).

Most diseases of the maxillary sinus can be managed by endoscope, which is used mostly to perform standard middle meatal antrostomy (MMA) ([@ref-13]). For benign lesions such as inverted papillomas, endoscopic medial maxillectomies are often performed for better operating field and management of the tumor attachment site ([@ref-23]; [@ref-25]). While it is almost impossible to resolve every detail of the disease with conservative approach, more extended procedures are performed at increased risk of surgery-related morbidities ([@ref-23]; [@ref-25]; [@ref-17]; [@ref-3]). [@ref-18] introduced the surgical creation of a corridor made by breaking a hole through the medial wall of prelacrimal recess (PLR), which is usually one of the most difficult positions to manipulate during standard MMA. This surgical corridor can provide an unobstructed view of almost any aspect of the maxillary inner linings. This improved visualization of the operating field can reduce the risks associated with endoscopic procedures ([@ref-25]; [@ref-17]; [@ref-3]).

[@ref-27], [@ref-28] have promulgated the use of the endoscopic PLR approach (EPLA) to manage a variety of pathologies of the maxillary sinus and deep areas of the skull base. The use of the EPLA has been reported to provide results comparable to those of conventional external procedures ([@ref-15]). However, its application has mostly been focused on the removal of neoplasms and no studies have been performed to assess post-treatment life-quality following EPLA ([@ref-15]; [@ref-29]; [@ref-26]; [@ref-16]). Therefore, in this study, we retrospectively reviewed the clinical applications of endoscopic PLR approach in the surgical treatment of different maxillary pathologies. Patients were followed up to assess functional treatment outcomes (patient-reported overall health and symptom severity) as well as adverse events and need for revision surgery.

Materials and Methods
=====================

Study design and patient eligibility
------------------------------------

We identified 21 adult patients receiving surgical procedures utilizing the endonasal endoscopic prelacrimcal recess approach (EPLA) from February 2015 to October 2018 in two tertiary care referral centers retrospectively. These patients may have also had additional endoscopic sinus surgeries or deviated septum corrections when deemed necessary by a surgeon based on pathology, extent of disease, or a patient's specific complaints prior to surgery. All patients enrolled in this study were recommended EPLAs because their diseases had been considered too difficult to treat using standard MMA alone. The protocol of this study was approved by the institutional review board of Kaohsiung Chang Gung Memorial Hospital (IRB No: 201900695B0). Written consents of the participants are not needed because of the retrospective nature of our study design.

All patients received high-resolution sinus computed tomography scans (1.0-mm slices in the axial view) to assess degree of inflammation. Sinus disease was scored based on modified-Lund--Mackay scores ([@ref-21]) of the diseased side and further categorized using the Krous staging system ([@ref-14]) or American Joint Committee on Cancer (AJCC) TNM classifications, depending on whether they were sinonasal papillomas or malignancies. PLR space was measured as follows. Antero-posterior (AP) diameter was first defined as the distance from pyriform aperture to the nasolacrimal duct (NLD) by identifying the inferior-most aspect of NLD on coronal view and then transposing that to axial view. The height of medial PLR was measured starting at the level of the superior-most aspect of the NLD to the nasal floor, as described in [@ref-12]. Other demographic data including age, gender, initial symptoms and their durations, image findings and known surgical history of each patient were also collected from each patient prior to surgery. After surgery, patients received a series of follow-up examinations in 3--6 visits spaced 1--4 weeks apart, depending on endoscopic findings and specific needs of the patient. Daily saline irrigation and intranasal corticosteroid spray were performed for post-treatment cares. Short-term oral medications were prescribed only for symptomatic patients. Revision surgery was performed if disease recurred.

Outcome assessment
------------------

We assessed interval changes in patient-reported outcomes between initial baseline evaluations and the last follow-up date. Functional outcome measurements included self-rated visual analog scale for current overall health (zero being worst imaginable and 10 as best imaginable) and self-rated 22-item Sino-Nasal Outcome Test (SNOT-22) to assess sinonasal symptom severity ([@ref-7]). Other outcomes were incidence and characterization of treatment-associated adverse events and need for revision surgery. Follow-up time was defined as the time between the first visit with an otolaryngologist for diagnosis to the last documented follow-up date.

Surgical technique
------------------

All surgical procedures were performed with patients under general anesthesia. EPLA was performed before the other procedures for patients scheduled to receive endoscopic PLR approach for maxillary sinus lesions. To perform these procedures using the PLR approach, we first administered local anesthesia to the axilla of inferior turbinate using a 4 mm, 18 cm length zero degree rod-lens endoscope (Karl Storz Endoscopy, Tuttlingen, Germany). A 15-blade was used to create a curvilinear incision from the lateral nasal cavity to the nasal floor, pathway crossing just anteriorly to the head of inferior turbinate. The inferior turbinate-nasolacrimal duct (IT-NLD) flap was then elevated subperiosteally by a suction elevator pulling it toward the mucosal portion of the naso-lacrimal duct and placed medially. Using a 4 mm chisel to remove the head of inferior concha bone and part of frontal process of maxillary bone, we penetrated the antero-medial aspect of maxillary sinus. The entrance was further enlarged using a Kerrison Rongeurs and/or drilling burr. When operating space was not easily accessible and a wider working area was needed, we drilled out part of the anterior maxillary wall to make way extent our surgical fulcrum laterally. All the diseased mucosa as well as neoplasms were removed. The underlying hyperplastic bones were drilled out and cauterized electrically in patients with sinonasal papillomas ([@ref-10]). Additionally, the medial bony compartment was taken out altogether when the lesions were closely attached to the natural ostium and/or medial aspect of maxillary sinus. For inflammatory lesions, much of the underlying sinus mucosa was preserved as possible while the nidus were meticulously trimmed. The IT-NLD flap was re-draped onto its primary position suturing the incision site with 4-O vicryl. In some patients, an inferior meatotomy was created to facilitate future observation during following visits ([Fig. 1](#fig-1){ref-type="fig"}).

![Inferior antrostomy is created after pre-lacrimal approach combined with medial maxillectomy.\
Inferior antrostomy was created to facilitate post-operative follow-up in inverted papilloma patients with risk of recurrence.](peerj-08-8331-g001){#fig-1}

Statistical analyses
--------------------

Categorical variables were expressed as frequency and percentage. Descriptive parametric data were expressed using mean, standard deviation (SD), and range. We used median and interquartile range (IQR) to express subjective metrics (VAS and SNOT-22 included). Their interval changes between different groups were tested using Wilcoxon signed rank test. The differences between two groups were tested using Mann--Whitney *U* test. *P*-value \< 0.05 was considered significant. All statistical operations were performed using IBM SPSS 22.0 statistical software (IBM Corp. Released 2013. IBM SPSS Statistics for Windows, Version 22.0. Armonk, NY: IBM Corp., Chicago, IL, USA).

Results
=======

Patients characters
-------------------

A total of 21 patients (16 males and five females) with 22 lesion sites received surgical procedures utilizing the endonasal endoscopic prelacrimcal recess approach (EPLA) at our two hospitals. The mean (standard deviation (SD)) age at diagnosis was 51.7 (14.5) years (range 17--81 years) and mean follow-up after surgery was 12.7 months (range 1.4--41.5 months). Fourteen patients underwent these procedures as primary surgeries; the other seven received these procedures as revisions ([Table 1](#table-1){ref-type="table"}). The other procedures included septoplasty (*n* = 2), endoscopic sinus surgery (*n* = 14), and inferior meatotomies (*n* = 3). Inferior meatotomies were created for facilitating postoperative investigation in two patients with diffuse papilloma and in one patient with trauma-related maxillary mucocele. Five (71.4%) of these seven revision patients received at least two interventions ([Table 1](#table-1){ref-type="table"}). As can be seen in [Table 1](#table-1){ref-type="table"}, a summary of initial presentations, the most frequent symptoms were nasal obstruction and nasal discharge followed by blood streaks within nasal drainages/blood tinged sputum. The duration of symptoms ranged from 30 days to 72 months (mean (SD): 17.2 (24.2) months).
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###### Demographic characteristic of 21 patients with underwent endonasal endoscopic prelacrimal recess approach.

![](peerj-08-8331-g003)

  Variables                                             Sinonasal papilloma *n* = 9   Non papilloma *n* = 12
  ----------------------------------------------------- ----------------------------- ------------------------
  Age, mean (SD)                                        57.0 ± 15.4                   47.8 ± 13.7
  Gender, *n* (%)                                                                     
  Male                                                  7 (77.8)                      9 (75)
  Female                                                2 (22.2)                      3 (25)
  Initial symptoms, *n* (%)                                                           
  Nasal airway obstruction                              4 (44.4)                      3 (25)
  Nasal discharge/discolored post nasal drips           2 (22.2)                      6 (50)
  Facial & head pain/pressures                          0                             5 (41.7)
  Hyposmia/anosmia                                      0                             1 (8.3)
  Blood tinged sputum/rhinorrhea                        5 (55.6)                      1 (8.3)
  Ophthalmologic manifestations                         0                             2 (16.6)
  Asymptomatic                                          1 (11.1)                      0
  CT Lund-Mackay scores, mean (SD)                                                    
  Maxillary sinus (modified)                            3.0 ± 0.7                     2.9 ± 1.2
  Total                                                 5.7 ± 6.8                     4.6 ± 5.0
  Measured nasolacrimal complex parameters, mean (SD)                                 
  Antero-posterior dimension (mm)                       5.2 ± 1.3                     5.6 ± 1.5
  Height (mm)                                           26.4 ± 3.7                    27.3 ± 5.0
  Revision procedures, *n* (%)                          4 (44.4)                      3 (25)
  Complications, *n* (%)                                                              
  Transient dental/cheek numbness                       9 (100)                       2 (16.7)
  Epistaxis                                             1 (11.1)                      0
  Delayed wound healing                                 1 (11.1)                      0

**Note:**

CT, computed tomography; SD, standard deviation.

Pathologies and imaging features
--------------------------------

Patient characteristics and disease features are summarized in [Table 1](#table-1){ref-type="table"}. Three of the patients (14.3%) had inflammatory sinonasal disorders (two primary chronic rhinosinusitis and one recurrent bilateral CRS with nasal polyps). Eleven patients had benign neoplastic lesions within the maxillary sinus. Of these 11 patients, nine patients (81.8%; eight unilateral, one bilateral) had sinonasal papillomas (nine inverted, one exophytic) ([Fig. 2A](#fig-2){ref-type="fig"}), one had a sinonasal organized hematoma, and the other had a cavernous hemagioma. Three patients had odontogenic cysts, including two patients with comorbid maxillary ectopic teeth ([Fig. 2B](#fig-2){ref-type="fig"}). Within the remaining four patients, two patients presented trauma-related disorders (an orbital fracture requiring medial and inferior orbital repair as seen in [Fig. 2C](#fig-2){ref-type="fig"} and a maxillary mucocele that developed decades after facial trauma) and the other two patients with individual malignancies (lacrimal duct adenoid cystic carcinoma and recurrent buccal cancer with involvement to the infratemporal fossa) both underwent pathology obtainment by EPLA. The extent of disease and locations of the papillomas within maxillary sinus can be found in [Table 2](#table-2){ref-type="table"}.

![Pre-lacrimal approach is used to treat different maxillary sinus pathologies.\
Endoscopic pre-lacrimal approach for (A) left maxillary sinus inverted papilloma (B) left orbital floor defect repair with medpor (C) right maxillary sinus ectopic tooth removal.](peerj-08-8331-g002){#fig-2}
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###### Characteristic features of patients with sinonasal papilloma.
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  Patient number   Gender   Age   Pretreatment VAS   Pretreatment SNOT-22   Disease extent within maxillary sinus (disease side)   Follow-up time, months   Previous operation
  ---------------- -------- ----- ------------------ ---------------------- ------------------------------------------------------ ------------------------ --------------------
  1                M        59    8                  17                     M, P (L)                                               6                        N
  2                M        56    1                  2                      M, P (L)                                               17                       N
  3                M        30    N/A                N/A                    M, A, L (R)                                            37                       Y
  4                F        49    3                  27                     P, L (L)                                               7                        N
  5                M        44    5                  18                     I, M (L)                                               7                        N
  6                M        71    0                  2                      A, I (L)                                               7                        N
  7                F        54    10                 85                     A (B)                                                  42                       N
  8                M        81    4                  17                     ALL (L)                                                41                       Y
  9                M        69    6                  20                     A, L, P (R)                                            20                       Y

**Note:**

VAS, visual analog scales; SNOT-22, 22-item Sino-Nasal Outcomes Test; M, medial; P, posterior; L, lateral; A, anterior; I, inferior; N/A, not available; N, no; Y, yes.

Average AP diameter was 5.5 (1.4) mm, and mean PLR medial wall height 26.9 (4.2) mm (range 19--34.9 mm). AP diameter of three diseased sides is greater than 7 mm whereas the measurement of the remaining 19 sides ranged from 3 mm to 7 mm. We did not find difference of modified-Lund--Mackay scores between patients with sinonasal papillomas and chronic rhinosinusitis (3.0 (IQR 2.0--3.5) vs. 4.0 (IQR 4.0--4.0), *P* = 0.064). The mean (SD) values for pretreatment SNOT-22 and VAS are 32.6 (22.1) and 6.7 (3.4), respectively. Patients who did not have papillomas reported statistically higher VAS ratings and SNOT-22 scores than those with papillomas ([Table 3](#table-3){ref-type="table"}).
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###### Outcomes of patients treated with endoscopic prelacrimal recess approach.
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                   Pre-treatment           Post-treatment          *P*-value
  ---------------- ----------------------- ----------------------- -----------
                   VAS, median (IQR)       VAS, median (IQR)       
  Papillomas       4.5 (1.5--7.5)          1.5 (0--3.5)            0.061
  Non-papillomas   8.8 (7.3--10.0)         1.8 (0.3--3.2)          0.012
  *P*-value        0.050                   0.867                   
                   SNOT-22, median (IQR)   SNOT-22, median (IQR)   
  Papillomas       17.5 (5.8--25.3)        8.0 (3.3--11.0)         0.176
  Non-papillomas   37.5 (26.5--50.3)       13.5 (10.8--28.8)       0.012
  *P*-value        0.021                   0.121                   

**Note:**

VAS, visual analog scales; SNOT-22, 22-item Sino-Nasal Outcomes Test; IQR, interquartile range.

Outcomes and complication profiles
----------------------------------

Within these 21 patients, five patients did no complete subjective outcome measurements (SNOT-22 and VAS). Finally, 16 patients were enrolled in functional outcomes analysis measured at the last clinical visit after primary EPLAs. There were no significant differences in post-treatment patient-reported outcomes between those with sinonasal papillomas and those with other pathologies ([Table 3](#table-3){ref-type="table"}). Patients who did not have papillomas reported significantly improved VAS ratings and SNOT-22 scores ([Table 3](#table-3){ref-type="table"}, both *P*-values \< 0.05), while individuals with papillomas also reported improved VAS ratings and SNOT-22 scores, though without statistical significance ([Table 3](#table-3){ref-type="table"}). There was no disease recurrence during the follow-up period.

A total of 11 patients had 13 adverse events. Papilloma patients had a significantly higher incidence of post-operative complications, compared to patients with other pathologies (*n* = 11 vs. *n* = 2). The most commonly seen complication was paresthesia (*n* = 11) of cheek and tooth, and all symptoms of this complication resolved within 6 months. Patients with AP diameter ranged from 3 mm to 7 mm tend to have higher prevalence of surgery-associated neural sequels, compared with individuals with AP diameter greater than 7 mm (10/19, 52.6% vs. 1/3, 33%, respectively), though of no statistical significance (*P* = 1.00). One patient had delayed wound healing resulting from a prior submucosal turbinectomy allegedly caused by post-surgical scarring. Additionally, one patient developed epistaxis soon after the surgery. No nasal lacrimal ducts or negative esthetic issues (i.e., nasal alar collapse/soft tissues depressions) were found.

Discussion
==========

This study found that EPLA-treated patients reported improved VAS ratings and SNOT-22 scores over time, with mean improvements of 4.2 and 17.6 points, respectively. These scores suggest significant improvement in quality of life after EPLAs. Although we encountered treatment-associated adverse events, most of them are paresthesia occurred in inverted papilloma cases. However, all adverse events were all manageable and the sensory deficits subsided within 6 months. These findings suggest that the endoscopic PLR approach can be used safely and effectively to treat a variety of maxillary sinus pathologies.

In the surgical treatment of diseases originating from different sites of the maxillary sinus, the endoscopic pre-lacrimal approach makes possible the management of almost any aspect of internal linings. Especially the anterior and inferior aspect (e.g., alveolar recess and PLR), which are locations that traditional surgical corridors can hardly access ([@ref-18]; [@ref-27], [@ref-28]; [@ref-15]; [@ref-29]; [@ref-26]; [@ref-16]). In select cases in which disease is located far laterally, surgeons can drill the pyriform aperture and/or part of anterior maxillary wall to extend surgical fulcrum ([@ref-23]; [@ref-18]; [@ref-27]).

One recent study has reported that operations employing EPLA to treat maxillary or retro-maxilla lesions can achieve outcomes comparable to those achieved by traditional open approaches performed by experienced hands ([@ref-28]; [@ref-15]). However, before we try to implement this technique more widely, some of its disadvantages need to be understood. The first being that the inferior turbinate-nasal lacrimal duct mucosal flap is re-draped onto its original position, the anterior half of the maxillary sinus (especially the alveolar recess inferiorly and zygomatic recess laterally) is difficult to be evaluated even with the use of flexible endoscopy post-operatively ([@ref-29]). Therefore, additional inferior meatotomy may be necessary for full-filled surveillance for patients with high risk of disease recurrence ([@ref-29]). Further, post-surgical debridement and saline delivery are less convenient in comparison with standard endoscopic medial maxillectomy ([@ref-23]). Still another challenge is that EPLA must be very carefully performed when treating neoplasms involving or infiltrating the inferior turbinate, nasolacrimal complex or medial wall of the maxillary sinus ([@ref-18]; [@ref-27]). In addition, overzealous manipulation of mucosa within alveolar recess should be avoided to prevent inadvertent trauma to the minor branches of anterior superior alveolar nerve (branches from the infraorbital nerve running within the maxilla). Care must also be taken to avoid dental injury because first and second molar tooth are dehiscent into the maxillary sinus, which has been reported to occur in 2% of normal population ([@ref-6]).

Initially EPLA for neoplastic lesions were designed to provide a corridor to allow the management of lesions within infratemporal and pterygopalatine fossa tumors ([@ref-28]). Recently, its use has been extended to the treatment of maxillary neoplasms, mostly sinonasal inverted papillomas (SNIPs) ([@ref-27]; [@ref-15]; [@ref-29]; [@ref-26]). The benefits of EPLAs over standard endoscopic maxillectomies when treating SNIPs include its ability to preserve as many normal structures as possible ([@ref-23]), which makes wound healing faster, and its ability to avoid alter turbulent nasal airflow due to preserve of inferior turbinate ([@ref-5]). It has also been associated with less lacrimal pathway obstruction and fewer thick crusting because more of the epithelium is preserved ([@ref-11]). In their multicenter retrospective study, [@ref-29] reported recurrence rates in 71 Krous staged III SNIPs patients treated with EPLAs to be similar to those reported by [@ref-17] performing the largest endoscopically cohort study to date. However, patients in [@ref-29] were spared from post-operative mucocele developments and negative naso-lacrimal complex sequelae ([@ref-17]; [@ref-29]). [@ref-3], using extended endoscopic maxillectomies exclusively, also found significantly greater number for sensory deficits and esthetic problems than [@ref-29] reported. Three studies of EPLA SNIPs resections in relatively small patient groups have recently reported EPLAs to result in favorable local control rates, though they did not investigate post-surgery quality-of-life ([@ref-15]; [@ref-26]; [@ref-16]). Our eight sinonasal papillomas patients reported a median SNOT-22 score of eight after resection, slightly lower than the scores reported by a previously reported case series ([@ref-9]). Although statistical significance was not reached in our study, our results suggest improvements quality of life metrics after EPLA in these patients.

The proposed mechanisms for relatively higher incidence of transient neural sequel in our sinonasal papilloma patients are illustrated as the follows. The first is the majority of our study population has type II PLR (AP diameter ranged from 3 mm to 7 mm) ([@ref-20]). In an imaging study investigating the feasibility of EPLAs, [@ref-20] concluded more bone removal and probable translation tear sac are needed in type II subjects in comparison to those with type III (AP \> 7 mm). More bone removal might imply higher probabilities for nerve insults. Another is our exclusive performance of bone drilling on tumor bed ([@ref-10]). We hypothesize the direct and indirect nerve injuries due to osculating and heating effects by drillings may be responsible for the relative higher incidence for transient sensory deficit. As for residual inferior meatotomy, [@ref-19] proposed an innovative method by performing mucosal incision and osteotomy at different levels to minimize such an adverse event.

Some studies have reported greater/faster symptoms reduction and less disease recurrence following surgeries compared with appropriate pharmaceutical managements alone in certain subgroups of chronic rhinosinusitis ([@ref-8]; [@ref-1]; [@ref-24]). However, the appropriateness of primary EPLAs to treat lesions due to inflammation in rhinosinusitis has not been addressed. Our reason for extending the use of EPLA to inflammatory maxillary disease is that EPLAs can offer intuitive viewing and more maneuvering space by zero degree endoscope. Thus, EPLAs may save more time than MMAs without additional complications, especially when treating cases in which inflammatory polyps full of maxillary sinus. In these cases, stripping lesions arising from the anterior and/or medial aspect of maxillary sinus (e.g., alveolar or PLR) present an obstacle for standard MMA approach ([@ref-23]; [@ref-12]). Nonetheless, further studies are needed to elucidate whether patients with inflammatory maxillary disease undergoing EPLAs have results comparable with those treated with conventional MMAs.

This study has some limitations. One limitation is its relatively small sample size and a lack of a control cohort treated with other surgical strategies. This made further comparisons of multiple endpoints among different cohorts with maxillary lesions difficult. Another limitation is that because we only had access to post-operative outcomes approximate 6 months later, we could not determine whether reduced inflammation reached nadir after surgical treatment using EPLA. An additional limitation is that we remain unclear regarding the altered extent of nasal airway resistance and maxillary sinus mucociliary clearance post-operatively. Future investigations are needed to verify long-term rhinologic manifestations. Still another is we did not analyze influencing factors (e.g., laterality [@ref-4], surgical extent [@ref-2], comorbid rhinitis, and concomitant surgical procedures, etc) in the current study. Considering their probable impacts on VAS rating and SNOT-22 scores, future studies are warranted to test their significance in the framework of EPLAs.

Conclusion
==========

In conclusion, we found that in addition to tumors, EPLAs can be used to safely and efficaciously treat various lesions within the maxillary sinus. This approach might be used to replace invasive or time-consuming surgical strategies currently used to manage certain pathologies. We found most common adverse event to be transient cheek/tooth numbness but they usually subsided within 6 months. Thus, with adequate patient counseling, symptoms reduction and improvements in life quality can be expected after receiving surgical treatment of maxillary sinus lesions using EPLAs.
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###### Raw data.

###### 

Click here for additional data file.

EPLA(s)

:   endoscopic prelacrimal recess approache(s)

SNOT-22

:   22-item Sino-Nasal Outcomes Test

VAS

:   visual analog scales

MMA

:   middle meatal antrostomy

PLR

:   prelacrimal recess

AJCC

:   American Joint Committee on Cancer

AP

:   antero-posterior

NLD

:   nasal lacrimal duct

IT-NLD

:   inferior turbinate-nasolacrimal duct

SD

:   standard deviation

IQR

:   interquartile range

SNIP(s)

:   sinonasal inverted papilloma(s)
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